Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
2012-01-01 Antonioli, E.; Guglielmelli, P.; Pieri, L.; Finazzi, M.; Rumi, E.; Martinelli, V.; Vianelli, N.; Luigia Randi, M.; Bertozzi, I.; De Stefano, V.; Za, T.; Rossi, E.; Ruggeri, M.; Elli, E.; Cacciola, R.; Cacciola, E.; Pogliani, E.; Rodeghiero, F.; Baccarani, M.; Passamonti, Francesco; Finazzi, G.; Rambaldi, A.; Bosi, A.; Cazzola, M.; Barbui, T.; Vannucchi, A. M.
How to manage polycythemia vera
2012-01-01 Passamonti, Francesco
How I treat polycythemia vera
2012-01-01 Passamonti, Francesco
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
2013-01-01 Harrison, C. N.; Mesa, R. A.; Kiladjian, J. J.; Al Ali, H. K.; Gisslinger, H.; Knoops, L.; Squier, M.; Sirulnik, A.; Mendelson, E.; Zhou, X.; Copley Merriman, C.; Hunter, D. S.; Levy, R. S.; Cervantes, F.; Passamonti, Francesco; Barbui, T.; Barosi, G.; Vannucchi, A. M.
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment
2012-01-01 Thiele, J; Orazi, A; Kvasnicka, Hm; Franco, V; Boveri, E; Gianelli, U; Gisslinger, H; Passamonti, Francesco; Tefferi, A; Barbui, T.
The how and why of a firm’s approach to CSR and sustainability: A case study of a large European company
2016-01-01 Pistoni, ANNA ISIDE EUFEMIA; Songini, L.; Perrone, O.
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene
2013-01-01 Rumi, E.; Milosevic, J. D.; Casetti, I.; Dambruoso, I.; Pietra, D.; Boveri, E.; Boni, M.; Bernasconi, P.; Passamonti, Francesco; Kralovics, R.; Cazzola, M.
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
2014-01-01 H. L., Geyer; R. M., Scherber; A. C., Dueck; J. J., Kiladjian; Z., Xiao; S., Slot; S., Zweegman; F., Sackmann; A. K., Fuentes; D., Hernandez Maraver; K., Dohner; C. N., Harrison; D., Radia; P., Muxi; C., Besses; F., Cervantes; P. L., Johansson; B., Andreasson; A., Rambaldi; T., Barbui; A. M., Vannucchi; Passamonti, Francesco; J., Samuelsson; G., Birgegard; R. A., Mesa
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.
2012-01-01 Barbui, T; Thiele, J; Carobbio, A; Passamonti, Francesco; Rumi, E; Randi, Ml; Bertozzi, I; Vannucchi, Am; Gisslinger, H; Gisslinger, B; Finazzi, G; Ruggeri, M; Rodeghiero, F; Rambaldi, A; Gangat, N; Tefferi, A.
Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis).
2012-01-01 Barbui, T; Finazzi, G; Carobbio, A; Thiele, J; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Gisslinger, H; Buxhofer Ausch, V; De Stefano, V; Betti, S; Rambaldi, A; Vannucchi, Am; Tefferi, A.
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm
2012-01-01 Rumi, E.; Casetti, I.; Pietra, D.; Elena, C.; Ambaglio, I.; Pascutto, C.; Passamonti, Francesco; Cazzola, M.
Clinical Predictors of Outcome in MPN
2012-01-01 Passamonti, Francesco; Maffioli, M.; Merli, M.; Ferrario, A.; Caramazza, D.
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
2014-01-01 Barosi, G.; Tefferi, A.; Besses, C.; Birgegard, G.; Cervantes, F.; Finazzi, G.; Gisslinger, H.; Griesshammer, M.; Harrison, C.; Hehlmann, R.; Hermouet, S.; Kiladjian, J. J.; Kröger, N.; Mesa, R.; Mc Mullin, M. F.; Pardanani, A.; Passamonti, Francesco; Samuelsson, J.; Vannucchi, A. M.; Reiter, A.; Silver, R. T.; Verstovsek, S.; Tognoni, G.; Barbui, T.
Cardiovascular events and intensity of treatment in polycythemia vera
2013-01-01 Marchioli, R.; Finazzi, G.; Specchia, G.; Cacciola, R.; Cavazzina, R.; Cilloni, D.; De Stefano, V.; Elli, E.; Iurlo, A.; Latagliata, R.; Lunghi, F.; Lunghi, M.; Marfisi, R. M.; Musto, P.; Masciulli, A.; Musolino, C.; Cascavilla, N.; Quarta, G.; Randi, M. L.; Rapezzi, D.; Ruggeri, M.; Rumi, E.; Scortechini, A. R.; Santini, S.; Scarano, M.; Siragusa, S.; Spadea, A.; Tieghi, A.; Angelucci, E.; Visani, G.; Vannucchi, A. M.; Barbui, T.; Passamonti, Francesco
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
2013-01-01 Rumi, E.; Pietra, D.; Guglielmelli, P.; Bordoni, R.; Casetti, I.; Milanesi, C.; Sant’Antonio, E.; Ferretti, V.; Pancrazzi, A.; Rotunno, G.; Severgnini, M.; Pietrelli, A.; Astori, C.; Fugazza, E.; Pascutto, C.; Boveri, E.; Passamonti, Francesco; De Bellis, G.; Vannucchi, A.; Cazzola, M.
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT.
2012-01-01 Passamonti, Francesco; Thiele, J; Girodon, F; Rumi, E; Carobbio, A; Gisslinger, H; Kvasnicka, Hm; Ruggeri, M; Randi, Ml; Gangat, N; Vannucchi, Am; Gianatti, A; Gisslinger, B; Müllauer, L; Rodeghiero, F; D'Amore, Es; Bertozzi, I; Hanson, Ca; Boveri, E; Marino, F; Maffioli, M; Caramazza, D; Antonioli, E; Carrai, V; Buxhofer Ausch, V; Pascutto, C; Cazzola, M; Barbui, T; Tefferi, A.
Cooperative Innovation: In Quest of Effective Partners. Evidence from Italian Firms
2015-01-01 Barzi, F.; Cortelezzi, Flavia; Marseguerra, G.; Zoia, M. G.
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
2014-01-01 Tefferi, A.; Lasho, T. L.; Finke, C. M.; Knudson, R. A.; Ketterling, R.; Hanson, C. H.; Maffioli, M.; Caramazza, D.; Passamonti, Francesco; Pardanani, A.
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
2014-01-01 Tefferi, A.; Wassie, E. A.; Guglielmelli, P.; Gangat, N.; Belachew, A. A.; Lasho, T. L.; Finke, C.; Ketterling, R. P.; Hanson, C. A.; Pardanani, A.; Wolanskyj, A. P.; Maffioli, M.; Casalone, R.; Pacilli, A.; Vannucchi, A. M.; Passamonti, Francesco
It is time to change thrombosis risk assessment for PV and ET?
2014-01-01 Passamonti, Francesco; Domenica, Caramazza; Mora, Barbara; Rosario, Casalone; Margherita, Maffioli
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN | 1-gen-2012 | Antonioli, E.; Guglielmelli, P.; Pieri, L.; Finazzi, M.; Rumi, E.; Martinelli, V.; Vianelli, N.; Luigia Randi, M.; Bertozzi, I.; De Stefano, V.; Za, T.; Rossi, E.; Ruggeri, M.; Elli, E.; Cacciola, R.; Cacciola, E.; Pogliani, E.; Rodeghiero, F.; Baccarani, M.; Passamonti, Francesco; Finazzi, G.; Rambaldi, A.; Bosi, A.; Cazzola, M.; Barbui, T.; Vannucchi, A. M. | |
| How to manage polycythemia vera | 1-gen-2012 | Passamonti, Francesco | |
| How I treat polycythemia vera | 1-gen-2012 | Passamonti, Francesco | |
| Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy | 1-gen-2013 | Harrison, C. N.; Mesa, R. A.; Kiladjian, J. J.; Al Ali, H. K.; Gisslinger, H.; Knoops, L.; Squier, M.; Sirulnik, A.; Mendelson, E.; Zhou, X.; Copley Merriman, C.; Hunter, D. S.; Levy, R. S.; Cervantes, F.; Passamonti, Francesco; Barbui, T.; Barosi, G.; Vannucchi, A. M. | |
| European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment | 1-gen-2012 | Thiele, J; Orazi, A; Kvasnicka, Hm; Franco, V; Boveri, E; Gianelli, U; Gisslinger, H; Passamonti, Francesco; Tefferi, A; Barbui, T. | |
| The how and why of a firm’s approach to CSR and sustainability: A case study of a large European company | 1-gen-2016 | Pistoni, ANNA ISIDE EUFEMIA; Songini, L.; Perrone, O. | |
| Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene | 1-gen-2013 | Rumi, E.; Milosevic, J. D.; Casetti, I.; Dambruoso, I.; Pietra, D.; Boveri, E.; Boni, M.; Bernasconi, P.; Passamonti, Francesco; Kralovics, R.; Cazzola, M. | |
| Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients | 1-gen-2014 | H. L., Geyer; R. M., Scherber; A. C., Dueck; J. J., Kiladjian; Z., Xiao; S., Slot; S., Zweegman; F., Sackmann; A. K., Fuentes; D., Hernandez Maraver; K., Dohner; C. N., Harrison; D., Radia; P., Muxi; C., Besses; F., Cervantes; P. L., Johansson; B., Andreasson; A., Rambaldi; T., Barbui; A. M., Vannucchi; Passamonti, Francesco; J., Samuelsson; G., Birgegard; R. A., Mesa | |
| Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis. | 1-gen-2012 | Barbui, T; Thiele, J; Carobbio, A; Passamonti, Francesco; Rumi, E; Randi, Ml; Bertozzi, I; Vannucchi, Am; Gisslinger, H; Gisslinger, B; Finazzi, G; Ruggeri, M; Rodeghiero, F; Rambaldi, A; Gangat, N; Tefferi, A. | |
| Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). | 1-gen-2012 | Barbui, T; Finazzi, G; Carobbio, A; Thiele, J; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Gisslinger, H; Buxhofer Ausch, V; De Stefano, V; Betti, S; Rambaldi, A; Vannucchi, Am; Tefferi, A. | |
| Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm | 1-gen-2012 | Rumi, E.; Casetti, I.; Pietra, D.; Elena, C.; Ambaglio, I.; Pascutto, C.; Passamonti, Francesco; Cazzola, M. | |
| Clinical Predictors of Outcome in MPN | 1-gen-2012 | Passamonti, Francesco; Maffioli, M.; Merli, M.; Ferrario, A.; Caramazza, D. | |
| Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) | 1-gen-2014 | Barosi, G.; Tefferi, A.; Besses, C.; Birgegard, G.; Cervantes, F.; Finazzi, G.; Gisslinger, H.; Griesshammer, M.; Harrison, C.; Hehlmann, R.; Hermouet, S.; Kiladjian, J. J.; Kröger, N.; Mesa, R.; Mc Mullin, M. F.; Pardanani, A.; Passamonti, Francesco; Samuelsson, J.; Vannucchi, A. M.; Reiter, A.; Silver, R. T.; Verstovsek, S.; Tognoni, G.; Barbui, T. | |
| Cardiovascular events and intensity of treatment in polycythemia vera | 1-gen-2013 | Marchioli, R.; Finazzi, G.; Specchia, G.; Cacciola, R.; Cavazzina, R.; Cilloni, D.; De Stefano, V.; Elli, E.; Iurlo, A.; Latagliata, R.; Lunghi, F.; Lunghi, M.; Marfisi, R. M.; Musto, P.; Masciulli, A.; Musolino, C.; Cascavilla, N.; Quarta, G.; Randi, M. L.; Rapezzi, D.; Ruggeri, M.; Rumi, E.; Scortechini, A. R.; Santini, S.; Scarano, M.; Siragusa, S.; Spadea, A.; Tieghi, A.; Angelucci, E.; Visani, G.; Vannucchi, A. M.; Barbui, T.; Passamonti, Francesco | |
| Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms | 1-gen-2013 | Rumi, E.; Pietra, D.; Guglielmelli, P.; Bordoni, R.; Casetti, I.; Milanesi, C.; Sant’Antonio, E.; Ferretti, V.; Pancrazzi, A.; Rotunno, G.; Severgnini, M.; Pietrelli, A.; Astori, C.; Fugazza, E.; Pascutto, C.; Boveri, E.; Passamonti, Francesco; De Bellis, G.; Vannucchi, A.; Cazzola, M. | |
| A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. | 1-gen-2012 | Passamonti, Francesco; Thiele, J; Girodon, F; Rumi, E; Carobbio, A; Gisslinger, H; Kvasnicka, Hm; Ruggeri, M; Randi, Ml; Gangat, N; Vannucchi, Am; Gianatti, A; Gisslinger, B; Müllauer, L; Rodeghiero, F; D'Amore, Es; Bertozzi, I; Hanson, Ca; Boveri, E; Marino, F; Maffioli, M; Caramazza, D; Antonioli, E; Carrai, V; Buxhofer Ausch, V; Pascutto, C; Cazzola, M; Barbui, T; Tefferi, A. | |
| Cooperative Innovation: In Quest of Effective Partners. Evidence from Italian Firms | 1-gen-2015 | Barzi, F.; Cortelezzi, Flavia; Marseguerra, G.; Zoia, M. G. | |
| CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons | 1-gen-2014 | Tefferi, A.; Lasho, T. L.; Finke, C. M.; Knudson, R. A.; Ketterling, R.; Hanson, C. H.; Maffioli, M.; Caramazza, D.; Passamonti, Francesco; Pardanani, A. | |
| Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients | 1-gen-2014 | Tefferi, A.; Wassie, E. A.; Guglielmelli, P.; Gangat, N.; Belachew, A. A.; Lasho, T. L.; Finke, C.; Ketterling, R. P.; Hanson, C. A.; Pardanani, A.; Wolanskyj, A. P.; Maffioli, M.; Casalone, R.; Pacilli, A.; Vannucchi, A. M.; Passamonti, Francesco | |
| It is time to change thrombosis risk assessment for PV and ET? | 1-gen-2014 | Passamonti, Francesco; Domenica, Caramazza; Mora, Barbara; Rosario, Casalone; Margherita, Maffioli |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- Articoli su Riviste35263
Data di pubblicazione
- In corso di stampa26
- 2020 - 202710432
- 2010 - 201911845
- 2000 - 20097910
- 1990 - 19993628
- 1980 - 19891162
- 1970 - 1979252
- 1967 - 19698
Editore
- Edizioni Luigi Pozzi Srl:via Pana...51
- Japadre Editore, L'Aquila36
- WILEY34
- Elsevier BV:PO Box 211, 1000 AE A...31
- ELSEVIER SCIENCE BV29
- Franco Angeli Riviste SRL:viale M...28
- Springer Verlag Germany:Tiergarte...28
- -Roma: [s.n.]. -Artegierre-Esseze...26
- Elsevier B.V.23
- Royal Society of Chemistry:Thomas...21
Rivista
- PHYSICAL REVIEW LETTERS216
- LA RADIOLOGIA MEDICA180
- NUCLEAR INSTRUMENTS & METHODS IN ...176
- ASTRONOMY & ASTROPHYSICS168
- MONTHLY NOTICES OF THE ROYAL ASTR...165
- PLOS ONE163
- PHYSICS LETTERS. SECTION B154
- SCIENTIFIC REPORTS153
- THROMBOSIS AND HAEMOSTASIS145
- IL PROTAGORA140
Serie
- PROCEEDINGS OF INTERNATIONAL MATH...1
Keyword
- Humans1627
- Female817
- Male695
- Middle Aged526
- COVID-19518
- Aged481
- Adult464
- Italy345
- SARS-CoV-2317
- Treatment Outcome240
Lingua
- eng18885
- ita2906
- fre60
- spa55
- ger35
- por14
- bul9
- rus8
- gre6
- chi3
Accesso al fulltext
- no fulltext24730
- reserved5245
- open5085
- restricted107
- partially open93
- mixed2
- embargoed1